Audi Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Audi Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, growt…

2016-01-22 Kakinada, Andhra Pradesh Active Unlisted Active Compliant
Share
Connect MCP
AP Audi Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Audi Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
77/100
Trust Score
Low Risk

Audi Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 77/100. Audi Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2016, operating in the Professional Services sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 10 Aug 2026 from the latest processed filings. Audi Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
77/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
40/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 3 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
GUTTULA DURGA RAO 01234567 Director 01/04/2018 6 yrs Approved
SHAIK AHAMAD ALI 01234567 Director 01/04/2018 6 yrs Approved
BABU RAO MODU 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
06

Ownership & Group Intelligence

Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Key managerial personnel: SHAIK AHAMAD ALI (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 40 · Distress 60
Growth signals & trust indicators
Operating for 10+ years.
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence81/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment60/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view49/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 12 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
23 Apr 2023
Director ceased
SHAIK AHAMAD ALI
28 Oct 2022
Director appointed
GUTTULA DURGA RAO (Director)
08 Sep 2022
Director ceased
PUSHPAVALLI GUSIDI
06 Sep 2022
Director appointed
SHAIK AHAMAD ALI (Managing Director)
Director appointed
BABU RAO MODU (Director)
02 Dec 2019
Director ceased
SUBRAMANYAM VIPPATAPU
Director ceased
KRISHNA KAVYA PERESETTY
29 Sep 2018
Director ceased
AMBATIPATI RAMALINGA MURTY
23 Nov 2016
Director ceased
KRISHNA KISHORE DOGIPARTHY
22 Jan 2016
Incorporated
Registered with Roc Vijayawada
10

Key Observations

Auto-generated from the data above
Revenue declined 38% over the last 2 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Sb Curative Care Limited U74110MH2019PLC334444 Tq. Udgir, Dist. Latur, Maharashtra, India
Moondust Events Management Private Limited U74140BR2015PTC024069 Patna, Bihar, India
Masa Advisors Private Limited U74900DL2011PTC221905 New Delhi, Delhi, India
Viablue U74110GJ2018PTC104402 Ghatlodia, Ahmedabad, Gujarat, India
Final Touch Home Solutions Private Limited U74110WB2015PTC206559 Kolkata, West Bengal, India
Trustbiz Taxnology Private Limited U74140MH2019PTC326231 Mumbai, Maharashtra, India
Red Ocean Shipping Management Private Limited U74140DL2015PTC288365 Delhi, Delhi, India
Radars Cargo Care Private Limited U74110TN2011PTC082031 Chennai, Tamil Nadu, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Audi Pharmaceuticals Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Audi Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Audi Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 77/100, distress signals and MSME payment-delay disclosures - know whether Audi Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Audi Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Audi Pharmaceuticals Private Limited an active company?

Audi Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Audi Pharmaceuticals Private Limited financially healthy?

Audi Pharmaceuticals Private Limited has a Financial Health Score of 40/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Audi Pharmaceuticals Private Limited?

Its overall Trust Score is 77/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Audi Pharmaceuticals Private Limited?

See the directors and ownership sections above for board and shareholding detail. 3 active director(s) are on record.

Does Audi Pharmaceuticals Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Audi Pharmaceuticals Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Audi Pharmaceuticals Private Limited?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.